IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78

Cancer Letters

Volumn 325, Issue 2, 2012, Pages 200-206

  Li, Chao ^a   Harada, Aki ^a   Oh, Youngman ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ad; Apoptosis; Breast cancer; Caspase 7; Drug resistance; ER; EV; GRP78; IGF; IGFBP; IGFBP 3; MOI

Indexed keywords

CASPASE 7; FULVESTRANT; GLUCOSE REGULATED PROTEIN 78; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 3;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CASPASE 7; CELL LINE, TUMOR; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE LIBRARY; HEAT-SHOCK PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN INTERACTION MAPPING; TAMOXIFEN; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84865660956     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.004     Document Type: Article

References (62)

1. American Cancer Society. Breast Cancer Facts & Figures 2011-2012. Atlanta: American Cancer, Society, Inc., 2011.
2. Jordan V.C. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat. Rep. 1976, 60:1409-1419.
3. Kangas L., Nieminen A.L., Blanco G., Gronroos M., Kallio S., Karjalainen A., Perila M., Sodervall M., Toivola R. A new triphenylethylene compound, fc-1157a. II. Antitumor effects. Cancer Chemother. Pharmacol. 1986, 17:109-113.
4. Gibson L., Lawrence D., Dawson C., Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst. Rev. 2009, (4):CD003370.
5. Dediu M., Median D., Alexandru A., Vremes G., Gal C., Gongu M. Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?. J. Buon. 2009, 14:375-379.
6. Parker M.G. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res. Treat. 1993, 26:131-137.
7. Bundred N.J., Anderson E., Nicholson R.I., Dowsett M., Dixon M., Robertson J.F. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res. 2002, 22:2317-2319.
8. Dowsett M., Nicholson R.I., Pietras R.J. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res. Treat. 2005, 93(Suppl. 1):S11-S18.
9. Mohan S., Baylink D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J. Endocrinol. 2002, 175:19-31.
10. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 1999, 20:761-787.
11. Jogie-Brahim S., Feldman D., Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr. Rev. 2009, 30:417-437.
12. Kim H.S., Ingermann A.R., Tsubaki J., Twigg S.M., Walker G.E., Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 2004, 64:2229-2237.
13. Oh Y., Muller H.L., Pham H., Rosenfeld R.G. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J. Biol. Chem. 1993, 268:26045-26048.
14. Ingermann A.R., Yang Y.F., Han J., et al. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J. Biol. Chem. 2010, 285:30233-30246.
15. Leal S.M., Liu Q., Huang S.S., Huang J.S. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J. Biol. Chem. 1997, 272:20572-20576.
16. Mishra S., Raz A., Murphy L.J. Insulin-like growth factor binding protein-3 interacts with autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and inhibits the AMF/PGI function. Cancer Res. 2004, 64:2516-2522.
17. Ikonen M., Liu B., Hashimoto Y., Ma L., Lee K.W., Niikura T., Nishimoto I., Cohen P. Interaction between the alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:13042-13047.
18. Oufattole M., Lin S.W., Liu B., Mascarenhas D., Cohen P., Rodgers B.D. Ribonucleic acid polymerase II binding subunit 3 (Rpb3), a potential nuclear target of insulin-like growth factor binding protein-3. Endocrinology 2006, 147:2138-2146.
19. Wu C., Yao G., Zou M., Chen G., Wang M., Liu J., Wang J., Xu D. N-acetylgalactosaminyltransferase 14, a novel insulin-like growth factor binding protein-3 binding partner. Biochem. Biophys. Res. Commun. 2007, 357:360-365.
20. Lee K.W., Ma L., Yan X., Liu B., Zhang X.K., Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J. Biol. Chem. 2005, 280:16942-16948.
21. Jia Y., Lee K.W., Swerdloff R., Hwang D., Cobb L.J., Sinha Hikim A., Lue Y.H., Cohen P., Wang C. Interaction of insulin-like growth factor-binding protein-3 and BAX in mitochondria promotes male germ cell apoptosis. J. Biol. Chem. 2010, 285:1726-1732.
22. Han J., Jogie-Brahim S., Harada A., Oh Y. Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-kappaB signaling. Cancer Lett. 2011, 307:200-210.
23. Yeung B.H., Kwan B.W., He Q.Y., Lee A.S., Liu J., Wong A.S. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis. Oncogene 2008, 27:6782-6789.
24. Brunner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C., Lippman J., Frandsen T., Spang-Thomsen M., Fuqua S.A., Clarke R. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997, 57:3486-3493.
25. Reddy R.K., Mao C., Baumeister P., Austin R.C., Kaufman R.J., Lee A.S. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J. Biol. Chem. 2003, 278:20915-20924.
26. Mohanraj L., Oh Y. Targeting IGF-I, IGFBPs and IGF-I receptor system in cancer: the current and future in breast cancer therapy. Recent. Pat. Anticancer Drug Discov. 2011, 6:166-177.
27. Jones R.A., Campbell C.I., Gunther E.J., Chodosh L.A., Petrik J.J., Khokha R., Moorehead R.A. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007, 26:1636-1644.
28. Peyrat J.P., Bonneterre J., Beuscart R., Djiane J., Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 1988, 48:6429-6433.
29. Cullen K.J., Yee D., Sly W.S., Perdue J., Hampton B., Lippman M.E., Rosen N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990, 50:48-53.
30. Cullen K.J., Allison A., Martire I., Ellis M., Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res. Treat. 1992, 22:21-29.
31. Arteaga C.L., Osborne C.K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989, 49:6237-6241.
32. Schedlich L.J., Graham L.D. Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc. Res. Tech. 2002, 59:12-22.
33. Oh Y., Muller H.L., Ng L., Rosenfeld R.G. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem. 1995, 270:13589-13592.
34. Gucev Z.S., Oh Y., Kelley K.M., Rosenfeld R.G. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996, 56:1545-1550.
35. Martin J.L., Ballesteros M., Baxter R.C. Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology 1992, 131:1703-1710.
36. Fontana J.A., Burrows-Mezu A., Clemmons D.R., LeRoith D. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 1991, 128:1115-1122.
37. Adamo M.L., Shao Z.M., Lanau F., Chen J.C., Clemmons D.R., Roberts C.T., LeRoith D., Fontana J.A. Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 1992, 131:1858-1866.
38. Martin J.L., Coverley J.A., Pattison S.T., Baxter R.C. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 1995, 136:1219-1226.
39. Shang Y., Baumrucker C.R., Green M.H. Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells. J. Biol. Chem. 1999, 274:18005-18010.
40. Yateman M.E., Claffey D.C., Cwyfan Hughes S.C., Frost V.J., Wass J.A., Holly J.M. Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production. J. Endocrinol. 1993, 137:151-159.
41. Olney R.C., Wilson D.M., Mohtai M., Fielder P.J., Smith R.L. Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. J. Endocrinol. 1995, 146:279-286.
42. Besset V., Le Magueresse-Battistoni B., Collette J., Benahmed M. Tumor necrosis factor alpha stimulates insulin-like growth factor binding protein 3 expression in cultured porcine sertoli cells. Endocrinology 1996, 137:296-303.
43. Rozen F., Zhang J., Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int. J. Oncol. 1998, 13:865-869.
44. Rajah R., Lee K.W., Cohen P. Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of bcl-2 phosphorylation. Cell Growth Differ. 2002, 13:163-171.
45. Colston K.W., Perks C.M., Xie S.P., Holly J.M. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J. Mol. Endocrinol. 1998, 20:157-162.
46. Nickerson T., Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J. Endocrinol. 1999, 160:223-229.
47. Bhattacharyya N., Pechhold K., Shahjee H., Zappala G., Elbi C., Raaka B., Wiench M., Hong J., Rechler M.M. Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J. Biol. Chem. 2006, 281:24588-24601.
48. Zappala G., Elbi C., Edwards J., Gorenstein J., Rechler M.M., Bhattacharyya N. Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha. Endocrinology 2008, 149:1802-1812.
49. Little E., Ramakrishnan M., Roy B., Gazit G., Lee A.S. The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. Crit. Rev. Eukaryot. Gene Expr. 1994, 4:1-18.
50. Bertolotti A., Zhang Y., Hendershot L.M., Harding H.P., Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2000, 2:326-332.
51. Malhi H., Kaufman R.J. Endoplasmic reticulum stress in liver disease. J. Hepatol. 2011, 54:795-809.
52. Jing G., Wang J.J., Zhang S.X. ER stress and apoptosis: a new mechanism for retinal cell death. Exp. Diabetes Res. 2012, 2012:589589.
53. Gonzalez-Gronow M., Selim M.A., Papalas J., Pizzo S.V. GRP78: a multifunctional receptor on the cell surface. Antioxid. Redox Signal. 2009, 11:2299-2306.
54. Dong D., Ni M., Li J., et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008, 68:498-505.
55. Lee A.S. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem. Sci. 2001, 26:504-510.
56. Li J., Lee A.S. Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 2006, 6:45-54.
57. Lee A.S. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007, 67:3496-3499.
58. Rao R.V., Niazi K., Mollahan P., Mao X., Crippen D., Poksay K.S., Chen S., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell-death program: a novel HSP90-independent role for the small chaperone protein p23. Cell Death Differ. 2006, 13:415-425.
59. Fu Y., Li J., Lee A.S. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 2007, 67:3734-3740.
60. Rauschert N., Brandlein S., Holzinger E., Hensel F., Muller-Hermelink H.K., Vollmers H.P. A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab. Invest. 2008, 88:375-386.
61. Misra U.K., Deedwania R., Pizzo S.V. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J. Biol. Chem. 2006, 281:13694-13707.
62. Misra U.K., Pizzo S.V. Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. Cancer Biol. Ther. 2010, 9:142-152.